SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. (Q50066726)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

title

SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

author name string

Robert M Bell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

publication date

10 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

7 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

page(s)

435-437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

7 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Regulation of signal transduction by reactive oxygen species in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Sodium influx through cerebral sodium-glucose transporter type 1 exacerbates the development of cerebral ischemic neuronal damage

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Glucagon and heart in type 2 diabetes: new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2817%2930314-5

7 January 2021

10.1016/S2213-8587(17)30314-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29030201%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference